BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24356540)

  • 1. Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients.
    Calò LA; Davis PA; Pagnin E; Dal Maso L; Maiolino G; Seccia TM; Pessina AC; Rossi GP
    J Hypertens; 2014 Feb; 32(2):331-8. PubMed ID: 24356540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gαq/p63RhoGEF interaction in RhoA/Rho kinase signaling: investigation in Gitelman's syndrome and implications with hypertension.
    Pagnin E; Ravarotto V; Maiolino G; Naso E; Davis PA; Calò LA
    J Endocrinol Invest; 2018 Mar; 41(3):351-356. PubMed ID: 28840514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced mRNA and protein content of rho guanine nucleotide exchange factor (RhoGEF) in Bartter's and Gitelman's syndromes: relevance for the pathophysiology of hypertension.
    Pagnin E; Semplicini A; Sartori M; Pessina AC; Calò LA
    Am J Hypertens; 2005 Sep; 18(9 Pt 1):1200-5. PubMed ID: 16182110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High angiotensin II state without cardiac remodeling (Bartter's and Gitelman's syndromes): are angiotensin II type 2 receptors involved?
    Calò LA; Montisci R; Scognamiglio R; Davis PA; Pagnin E; Schiavo S; Mormino P; Semplicini A; Palatini P; D'Angelo A; Pessina AC
    J Endocrinol Invest; 2009 Nov; 32(10):832-6. PubMed ID: 19605975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes.
    Calò LA; Pagnin E; Ceolotto G; Davis PA; Schiavo S; Papparella I; Semplicini A; Pessina AC
    J Hypertens; 2008 May; 26(5):938-45. PubMed ID: 18398336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling.
    Ravarotto V; Pagnin E; Maiolino G; Fragasso A; Carraro G; Rossi B; Calò LA
    J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1245-50. PubMed ID: 26240115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways.
    Calò LA; Puato M; Schiavo S; Zanardo M; Tirrito C; Pagnin E; Balbi G; Davis PA; Palatini P; Pauletto P
    Nephrol Dial Transplant; 2008 Sep; 23(9):2804-9. PubMed ID: 18344243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes.
    Calò LA; Maiolino G
    J Endocrinol Invest; 2015 Jul; 38(7):711-6. PubMed ID: 25740064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae: insights from Bartter's and Gitelman's syndromes, human models of endogenous angiotensin II signaling antagonism.
    Calò LA; Davis PA; Rossi GP
    J Hypertens; 2014 Nov; 32(11):2109-19; discussion 2119. PubMed ID: 25202962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proinflammatory/profibrotic effects of aldosterone in Gitelman's syndrome, a human model opposite to hypertension.
    Ravarotto V; Simioni F; Sabbadin C; Pagnin E; Maiolino G; Armanini D; Calò LA
    J Endocrinol Invest; 2019 May; 42(5):521-526. PubMed ID: 30136149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension.
    Ravarotto V; Pagnin E; Fragasso A; Maiolino G; Calò LA
    High Blood Press Cardiovasc Prev; 2015 Sep; 22(3):215-23. PubMed ID: 25759028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling.
    Pagnin E; Davis PA; Sartori M; Semplicini A; Pessina AC; Calò LA
    J Hypertens; 2004 Oct; 22(10):1963-9. PubMed ID: 15361768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular pathophysiology of Bartter's and Gitelman's syndromes.
    Koulouridis E; Koulouridis I
    World J Pediatr; 2015 May; 11(2):113-25. PubMed ID: 25754753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linking inflammation and hypertension in humans: studies in Bartter's/Gitelman's syndrome patients.
    Caló LA; Davis PA; Pagnin E; Schiavo S; Semplicini A; Pessina AC
    J Hum Hypertens; 2008 Mar; 22(3):223-5. PubMed ID: 18046435
    [No Abstract]   [Full Text] [Related]  

  • 15. ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications.
    Calò LA; Schiavo S; Davis PA; Pagnin E; Mormino P; D'Angelo A; Pessina AC
    J Nephrol; 2010; 23(4):472-7. PubMed ID: 20349406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The search for a link between inflammation and hypertension--contribution from Bartter's/Gitelman's syndromes.
    Pagnin E; Davis PA; Semplicini A; Calò LA
    Nephrol Dial Transplant; 2006 Aug; 21(8):2340-2. PubMed ID: 16611677
    [No Abstract]   [Full Text] [Related]  

  • 17. Gitelman's and Bartter's Syndromes: From Genetics to the Molecular Basis of Hypertension and More.
    Ravarotto V; Bertoldi G; Stefanelli LF; Nalesso F; Calò LA
    Kidney Blood Press Res; 2022; 47(9):556-564. PubMed ID: 35858584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SIRT1, heme oxygenase-1 and NO-mediated vasodilation in a human model of endogenous angiotensin II type 1 receptor antagonism: implications for hypertension.
    Davis PA; Pagnin E; Dal Maso L; Caielli P; Maiolino G; Fusaro M; Paolo Rossi G; Calò LA
    Hypertens Res; 2013 Oct; 36(10):873-8. PubMed ID: 23698802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling.
    Calò LA; Facco M; Davis PA; Pagnin E; Maso LD; Puato M; Caielli P; Agostini C; Pessina AC
    Hypertens Res; 2011 Sep; 34(9):1017-22. PubMed ID: 21654754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Miscellaneous non-inflammatory musculoskeletal conditions. Bartter's and Gitelman's diseases.
    Favero M; Calò LA; Schiavon F; Punzi L
    Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):637-48. PubMed ID: 22142744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.